HK Stock Market Move | BIOCYTOGEN-B(02315) rose by more than 5% again, the company recently officially entered the list of Hong Kong Stock Connect. Institutions say that the Thousand Mice and Ten Thousand Resistances are beginning to be realized.

Biocytogen-B (02315) rose by more than 5%, as of the time of writing, it had increased by 4.94% to HK$36.08, with a trading volume of HK$27.5841 million. On the news front, the Shanghai Stock Exchange and the Shenzhen Stock Exchange recently announced that Baiosei Graphene has been included in the list of Hong Kong stocks eligible for trading under the Stock Connect scheme, effective from December 24, 2025. This move marks another important milestone for the company after establishing a dual capital market platform "A+H", opening up the Hong Kong stock channel to mainland investors. Huafu Securities previously pointed out in a research report that the company's Thousand Rats and Ten Antibodies strategy has started to pay off, with antibody licensing driving performance growth. Considering the high growth and high barriers to entry of the company's business, a stable base in preclinical animal and pharmacological evaluation, the antibody development business has gradually entered a period of performance realization. Furthermore, potential new drug pipelines have the potential to add value. The initial rating is "buy".